Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study

Annals of Vascular Surgery · Elsevier

Аннотация

Publication date: Available online 25 October 2026 Source: Annals of Oncology Author(s): Brian I. Rini, Toni K. Choueiri, Martin H. Voss, Mauricio Burotto, Jan Oldenburg, Howard P. Gurney, Thomas R. Ferguson, Hans Hammers, Laurence Albiges, Yüksel Ürün, Roberto I. Romero Diaz, Mustafa Özgüroğlu, Patricio Yañez Weber, Elena Verzoni, Camillo Porta, Alexandra Drakaki, Jun Guo, Nobuaki Matsubara, Aiying Chen, Joseph E. Burgents

Читать у издателя →

Похожие статьи